VIVUS (VVUS) March Qsymia Shipments Rose 29%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
VIVUS (VVUS) Qsymia Growth Seen at 55% in Q1 from Q4
April 22, 2013 6:57 AM EDTVIVUS, Inc. (Nasdaq: VVUS) could see some upside Monday following new Qsymia data out recently from Symphony.
Bloomberg Industries noted that prescriptions for Qsymia rose 55 percent from Q412 to Q113. A total of 16,451 new prescriptions were issued from October through December... More
